SCHEMBL2362229

SCHEMBL2362229

COCCn1c(N)nc2cc(C(=O)OC)ccc21

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.58
PTGER4 P35408 11/20 0.57
ADORA2A P29274 1/20 0.56
TLR7 Q9NYK1 1/20 0.52
ITK Q08881 1/20 0.52
EHMT2 Q96KQ7 1/20 0.50
ALDH1A1 P00352 1/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CNR2 P34972 1/20 0.45
HCAR3 P49019 1/20 0.45
BACE1 P56817 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22382310 0.89 PTGER4 (0.63) KDM4EPTGER4ADORA2AALDH1A1KMT2A
SCHEMBL19436514 0.85 KDM4E (0.56) KDM4EPTGER4ADORA2AITKEHMT2
Bromide SCHEMBL23227960 0.84 KDM4E (0.55) KDM4EPTGER4ADORA2AITKEHMT2
SCHEMBL22121391 0.84 KDM4E (0.60) KDM4EPTGER4ADORA2ATLR7ITK
SCHEMBL14468545 0.83 KDM4E (0.54) KDM4EPTGER4ADORA2AITKEHMT2
SCHEMBL2362614 0.83 KDM4E (0.56) KDM4EPTGER4TLR7ITKEHMT2
SCHEMBL21437365 0.82 EHMT2 (0.71) KDM4EPTGER4ADORA2ATLR7ITK
SCHEMBL21310941 0.81 TLR7 (0.58) KDM4EPTGER4ADORA2ATLR7ITK
SCHEMBL30897550 0.81 KDM4E (0.56) KDM4EPTGER4ITKEHMT2ALDH1A1
SCHEMBL11947887 0.81 KDM4E (0.56) KDM4EPTGER4ITKEHMT2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396581-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. (US) 2022-12-15 US disclosed
US-20220396581-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. (US) 2022-12-15 US disclosed
US-11014935-B2 Compounds for the treatment of paramyxovirus viral infections Janssen Biopharma, Inc. (US) 2021-05-25 US disclosed
US-11014935-B2 Compounds for the treatment of paramyxovirus viral infections Janssen Biopharma, Inc. (US) 2021-05-25 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
US-20150238498-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2015-08-27 US disclosed
US-20150238498-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2015-08-27 US disclosed
US-20150238498-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2015-08-27 US disclosed
WO-2014031784-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS ALIOS BIOPHARMA, INC. (US) 2014-02-27 WO disclosed
WO-2011099832-A2 NOVEL BENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CRYSTALGENOMICS, INC. (KR) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150238498-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS SARS1, MAVS, ZC3HAV1 KDM4E 3296/4885PTGER4 1868/4885ADORA2A 3420/4885
US-20220396581-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS MAVS, SARS1, ZC3HAV1 KDM4E 3430/4885PTGER4 2538/4885ADORA2A 2491/4885
US-11014935-B2 Compounds for the treatment of paramyxovirus viral infections MAVS, SARS1, ZC3HAV1 KDM4E 3430/4885PTGER4 2538/4885ADORA2A 2491/4885
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS MAVS, SARS1, ZC3HAV1 KDM4E 3430/4885PTGER4 2538/4885ADORA2A 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.